Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson EDURANT / rilpivirine by Year
EDURANT / rilpivirine — U.S. operational growth YoY (%) (%)
Johnson & Johnson EDURANT / rilpivirine: -18.4% in FY2025, down 8.4 pts from a year earlier. That is the lowest of the 9 years on record here.
Where the FY2025 figure comes from
“|| US | 26 | 31 | (18.4) | (18.4) | —”
Source: Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | EDURANT / rilpivirine — U.S. operational growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | -18.4% | -8.4 pts | Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗ |
| FY2024 | Dec 29, 2024 | -10.0% | -6.3 pts | Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗ |
| FY2023 | Dec 31, 2023 | -3.7% | +7.1 pts | Form 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗ |
| FY2022 | Jan 1, 2023 | -10.8% | -3.2 pts | Form 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗ |
| FY2021 | Jan 2, 2022 | -7.6% | +3.6 pts | Form 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗ |
| FY2020 | Jan 3, 2021 | -11.2% | +2.5 pts | Form 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗ |
| FY2019 | Dec 29, 2019 | -13.7% | -13.7 pts | Form 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗ |
| FY2018 | Dec 30, 2018 | 0.0% | -11.5 pts | Form 8-K (a2018q4exhibit9915.htm, filed 2019-01-22) ↗ |
| FY2017 | Dec 31, 2017 | 11.5% | – | Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson EDURANT / rilpivirine (%), annual FY2017–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-edurant-us-ops-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.